De belles biotechs en neurosciences
14.11.16 – Biotechinfo – De belles biotechs en neurosciences
Meet one of the Most Impressive French Biotech Entrepreneurs
The previous executive profiles we did, namely on Joern Aldag and Philippe Dro, are hard acts to follow, but Bernard Gilly was more than up to it. Bernard has a broad set of achievements for a broad set of lessons…
Une “initiative” sera lancée pour promouvoir les biotechs dans la French Tech (Bpifrance)
PARIS, 2 novembre 2016 (APM) – Le directeur général du groupe Bpifrance, Nicolas Dufourcq, a fait savoir lors d’une conférence de presse mercredi qu’une “initiative” serait lancée dans les mois à venir afin de créer une “identité” pour les biotechs…
Le Figaro TV: Bernard Gilly (iBionext) explique comment des implants permettent de retrouver la vue
http://video.lefigaro.fr/figaro/video/bernard-gilly-ibionext-explique-comment-des-implants-permettent-de-retrouver-la-vue/5186987857001/
Une Start-up développant une caméra biomimétique lève 13.8M€
http://www.lepoint.fr/automobile/actualites/une-start-up-developpant-une-camera-biomimetique-leve-13-8-m-eur-25-10-2016-2078372_683.php
iBionext Growth Fund plus que 54 M€ à trouver
http://www.eei-biotechfinances.com/ibionext-growth-fund-plus-que-54-me-a-trouver/
iBionext moves into VC financing with €46M first close of growth fund
http://www.fiercebiotech.com/biotech/ibionext-moves-into-vc-financing-eu46m-first-close-growth-fund
iBionext lance un nouveau modèle de fonds en santé (Les Echos)
http://www.lesechos.fr/idees-debats/sciences-prospective/0211257715250-ibionext-lance-un-nouveau-modele-de-fonds-en-sante-2025384.php?W6hICmoSzUABWSHo.99
Gecko Biomedical raises €22.5 million led by Sofinnova Partners
Funds to support the expansion of Gecko’s biopolymers platform through clinical development and approval for multiple applications in tissue reconstruction. Financing includes Bpifrance, and historical investors. Paris, France, March 17, 2016 – Gecko Biomedical (“Gecko”), a medical device company developing…
GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy
PARIS, Feb. 29, 2016 (GLOBE NEWSWIRE) — GenSight Biologics S.A. (GenSight), a clinical-stage biotechnology company discovering and developing novel gene therapies for neurodegenerative retinal diseases, and in the future, of the central nervous system, today announced enrollment of the first…